$44M Chantix nitrosamine class action settlement

Pfizer has agreed to a $44 million class action settlement to resolve claims that its Chantix smoking cessation drug was contaminated with a nitrosamine, a cancer-causing agent.

The Chantix settlement benefits individuals and third-party payors who paid any amount of money for retail purchases of Chantix in the United States and its territories between Sept. 29, 2015, and Sept. 17, 2021.

Plaintiffs in the nitrosamine lawsuit claim that Pfizer failed to comply with current good manufacturing practices, which resulted in Chantix becoming contaminated with a nitrosamine. Nitrosamines are probable human carcinogens linked to stomach cancer, liver cancer and other cancers.

Chantix is a prescription medication manufactured by Pfizer that helps adults quit smoking by reducing cravings and withdrawal symptoms.

Pfizer has not admitted any wrongdoing but agreed to a $44 million class action settlement to resolve the allegations.

Under the terms of the Chantix settlement, class members can receive a cash payment based on the amount they paid for Chantix. Class members who paid a higher amount for the drug will receive a larger share of the net settlement fund. No payment estimates are available at this time.

The deadline for exclusion and objection is Sept. 14, 2026.

The final approval hearing for the class action settlement is scheduled for Oct. 13, 2026.

To receive a nitrosamine lawsuit payment, class members must submit a valid claim form by Sept. 14, 2026.

Who’s Eligible

The class action settlement benefits consumers and third-party payors who paid any amount of money for retail purchases of Chantix in the United States and its territories from Sept. 29, 2015, through Sept. 17, 2021.

Potential Award

Varies

Proof of Purchase

Documentation of their retail purchases of Chantix, such as pharmacy receipts, credit card statements or other documentation that reflects the amount paid for Chantix and the date of the purchase.

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

09/14/2026

Case Name

In re: Chantix (Varenicline) Marketing, Sales Practices and Products Liability Litigation (No. II), Case No. 22-md-3050-KPF, in the U.S. District Court for the Southern District of New York

Final Hearing

10/13/2026

Settlement Website

ChantixSettlement.com

Claims Administrator

Chantix Settlement
c/o A.B. Data Ltd.
P.O. Box 173137
Milwaukee, WI 53217
[email protected]
877-354-3912

Class Counsel

Ruben Honik
HONIK LLC

Defense Counsel

Loren H. Brown
DLA PIPER LLP